17 / 30
allied
academies
Page 69
Journal of Gastronenterology and Digestive Diseases
|
Volume 3
J u n e 2 5 - 2 6 , 2 0 1 8 | D u b l i n , I r e l a n d
GASTROENTEROLOGY
International Conference on
EVALUATION OF
MIR-32
AND
PTEN
GENES IN COLORECTAL
CANCER PATIENTS
Bita Sepehri, Milad asadi, Ahmad Shokohi
and
Behzad Baradran
Tabriz University of Medical Sciences, Iran
Background:
Genes involved in various cellular processes, such as cell cycle, apoptosis and cell migration, play an important role
in the process of colon cancer.
miR-32
and
PTEN
gene are two important genes that previous studies have confirmed their role
in cancer development. In the present study, the change in the relative expression level of these genes was analyzed through the
carcinogenesis phenomenon and the relative expression of these genes in response to common treatments in the laboratory was
evaluated on two LS180 and SW480 cell lines in colorectal caner as a third most common cancer in the world.
Methods:
Through the surgical procedure of colorectal cancer patients, a total of 50 tumor tissues and normal marginal tissue
was collected. After extraction of RNA, Real-time PCR was used to measure changes in gene expression. The differences in
expression level of mRNAs of these genes as well as changes in the expression of these genes in response to common treatments
were investigated by appropriate statistical tests. In statistical tests, P value <0.05 was considered significant level.
Results:
The level of expression of
miR-32
in tumor tissues increased compared to healthy peripheral tissues but this change
was not significant (P= 0.078). On the other hand, the level of
PTEN
gene expression in tumor tissues significantly decreased
compared to healthy tissue (P= 0.032), and this downregulation was related to cancer stage. The changes in expression of both
genes in both cell lines after treatment with oxaloplatin showed significant changes in expression level.
Conclusion:
Our findings demonstrated that the expression of
miR-32
and
PTEN
can be used as a diagnostic or predictive
biomarker for CRC. And both of genes play a role in the therapeutic pathways of the oxaloplatin, but more studies are needed to
validate this claim.
Sepehribrr@yahoo.comJ Gastroenterol Dig Dis 2018, Volume 3